← Leaderboards
Elizabeth Ann Fitzpatrick
University Of Tennessee Health Sci Ctr
$4,803,552
Attributed
$6,982,803
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,982,803 · 3
By mechanism
R01$4,588,400 · 2
UC7$2,394,403 · 1
Top collaborators
- Ladislau Christopher Kovari5 shared
- Raymond F. Schinazi5 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Michael W Quasney$2,301,140
- Donghoon Chung$13,304,441
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadAnimal ModelLungMolecularCellsAnimalsProgramsPneumoniaLaboratoriesBreathingAntigensAnosmiaAnti-Inflammatory AgentsAcidsAffinityClinical DevelopmentCharacteristicsAutomobile DrivingAqueousChemokineBiological Availability2019-NcovBindingAnalog
Grant awards (13)
Facility Management, Maintenance and Operation Core$766,697
UC7 · FY2025 · AI · contact PI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$642,901
R01 · FY2025 · AI
Facility Management, Maintenance and Operation Core$882,711
UC7 · FY2024 · AI · contact PI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$645,603
R01 · FY2024 · AI
Facility Management, Maintenance and Operation Core$744,995
UC7 · FY2023 · AI · contact PI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$648,225
R01 · FY2023 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$650,769
R01 · FY2022 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$681,379
R01 · FY2021 · AI
The Role of Neutrophils in Hypersensitivity Pneumonitis$292,000
R01 · FY2010 · HL · contact PI
The Role of Neutrophils in Hypersensitivity Pneumonitis$292,000
R01 · FY2009 · HL · contact PI
The Role of Neutrophils in Hypersensitivity Pneumonitis$158,632
R01 · FY2009 · HL · contact PI
The Role of Neutrophils in Hypersensitivity Pneumonitis$292,000
R01 · FY2008 · HL · contact PI
The Role of Neutrophils in Hypersensitivity Pneumonitis$284,891
R01 · FY2007 · HL · contact PI